Bronze Sponsor

Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to trigger powerful T-cell immune responses based on its proprietary oligoDOM® technology. Osivax’ mission is to develop universal vaccine candidates designed to provide long-term protection against viruses that mutate rapidly and otherwise require frequent and costly seasonal updates.